Oppenheimer Reiterates Outperform on Tyra Biosciences, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Matthew Biegler has reiterated an Outperform rating on Tyra Biosciences (NASDAQ:TYRA) and maintained a $28 price target.
July 03, 2024 | 5:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Matthew Biegler has reiterated an Outperform rating on Tyra Biosciences and maintained a $28 price target.
The reiteration of an Outperform rating and the maintenance of a $28 price target by a reputable analyst can boost investor confidence in Tyra Biosciences, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100